ioniq
-
IONIQ Sciences announces IP acquisition and License buyout
IONIQ Sciences announced that it has acquired from OT Acceptance, LLC certain intellectual property formerly licensed to the…
-
IONIQ Sciences recognized as “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021″
IONIQ Sciences, Inc. announced it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology…
-
IONIQ Sciences proudly announces that Mrs. Jan Poulsen is a Lung Cancer Hero
IONIQ Sciences Proudly Announces that Mrs. Jan Poulsen is a Lung Cancer Hero
-
IONIQ Sciences Announces MedTech Breakthrough Award for “Oncology Innovation of the Year 2021”
IONIQ Sciences Announces MedTech Breakthrough Award for “Oncology Innovation of the Year 2021”
-
Should a Struggling Medtech Company Get a Second Chance: Interview With IONIQ CEO Jared Bauer
Bauer explains the two key factors he looks at when determining whether a medical device company is worth…
-
IONIQ Sciences announces Aaron B. Dorny has joined its Board of Directors
IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors.
-
IONIQ Sciences Announces Dr. Benjamin Haibe-Kains has joined its Scientific Advisory Committee
On September 27, 2021, IONIQ Sciences announced that Dr. Benjamin Haibe-Kains has joined its Scientific Advisory Committee.
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
